Treatment of Intestinal Inflammation With Epicutaneous Immunotherapy Requires TGF-β and IL-10 but Not Foxp3(+) Tregs

Background: Inflammatory bowel disease (IBD) involves an increase in T effector cells in the intestines that disrupts the normal balance with T regulatory cells (Tregs). A therapy that restores this balance has the potential to treat IBD. We have shown that epicutaneous exposure to OVA induces Tregs...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xin, Berin, M. Cecilia, Gillespie, Virginia L., Sampson, Hugh A., Dunkin, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952322/
https://www.ncbi.nlm.nih.gov/pubmed/33717186
http://dx.doi.org/10.3389/fimmu.2021.637630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952322/
https://www.ncbi.nlm.nih.gov/pubmed/33717186
http://dx.doi.org/10.3389/fimmu.2021.637630

Ejemplares similares